

# Chapter VII

## Industry-Specific Media & Conferences

# Introduction

The landscape of conferences and media covering AI for Drug Discovery is a useful window into the broad patterns that are emerging among the industry's thought-leader, and the topics covered by journalists and conferences gives some indication as to how industry players regard the maturity and near-future prospects of the industry, as well as the topics and applications that are gaining the greatest prominence within the industry.

More than that, an understanding of the media and conference landscape surrounding the industry also gives some indication. Generally, we are seeing an increase in the number of conferences focused specifically on AI for Drug Discovery, as well as an increase in the prominence of AI for Drug Discovery panels in conferences aimed at traditional BioPharma executives. This year has also seen a broader degree of global coverage of AI for Drug Discovery at both niche and generalized BioPharma conferences. Whereas the USA dominated the conference landscape in the past several years, we are seeing an increasing number of conferences specifically dedicated for AI for Drug Discovery in the UK, EU and Asia-Pacific region.

We are also witnessing an increase in the number of articles appearing in the media about the topic of AI for Drug Discovery.

An interesting question is whether we are seeing an increase in the quality of coverage from journalists, and to what extent they are beginning to give a clearer and more objective picture of the industry's prospects and growth.

Generally speaking, we do see a decrease in the number of articles skeptical of the potential for AI to reduce the time and cost it takes to develop drugs, and of its potential to have a serious impact upon the BioPharma industry at all.

We are also seeing an increase in the number of articles that frame the topic in an objective light, discussing major roadblocks and what needs to be done in order to let the industry bear its fruit, rather than hailing it as a panacea that will transform the process of drug discovery within a year.

# Top 20 Global AI for Drug Discovery Conferences



**Conference**  
**AI Pharma**  
 10-11 Sep 2018 (remind.me)  
 Tokyo, Japan

Interested Going

Cambridge Healthtech Institute's Inaugural  
**Artificial Intelligence & Machine Learning for Drug Discovery**  
 27 NOVEMBER 2018  
 SHERATON LISBOA HOTEL & SPA | LISBON, PORTUGAL



Part of **WPC EUROPE** 9th Annual WORLD PRECINCTUAL CONGRESS

12th June 2018  
 De Vere Canary Wharf, London

**AI IN PHARMA: OPPORTUNITIES & CHALLENGES**

Get ahead of the curve in this AI strategy masterclass for executives in Pharma.  
 Pre-Conference Think-Tank



**ADVANCED MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT**

Berlin, Germany 19-20th June



**GPU TECHNOLOGY CONFERENCE** AGENDA ATTEND PRESENT EXHIBIT MORE

SILICON VALLEY MARCH 18-22, 2019

**HEALTHCARE & MEDICAL RESEARCH CONFERENCE SESSIONS**



**ASDEvents**  
 conference, seminars & trainings

**Artificial Intelligence in Pharma Industry Summit**

19 February, 2018 - 20 February, 2018,  
 Berlin, Germany



**The AI Health & Pharma Summit®**

Co-located with  
**The AI Summit LONDON**

14 JUNE 2018  
 ExCeL EXHIBITION CENTRE, LONDON



**Smi**  
 LINKING BUSINESS with INFORMATION



**DRUG DISCOVERY**

21ST MARCH TO 22ND MARCH 2018,  
 LONDON, UNITED KINGDOM



Cambridge Consultants

EVENT  
**AI in Pharma Summit 2018**

9th October 2018  
 Boston, MA  
 Venue: The State Room



## Global Pharma R&D Informatics and AI Congress

WHEN  
 29th-30th Oct 2018  
 Registration from 8am

WHERE  
 London, United Kingdom  
 Radisson Blu Edwardian Heathrow

Home / Conferences / ARTIFICIAL INTELLIGENCE TO SPEED UP DRUG DISCOVERY: THE REVOLUTIONARY ROAD TO ADVANCING INNOVATION

**ARTIFICIAL INTELLIGENCE TO SPEED UP DRUG DISCOVERY: THE REVOLUTIONARY ROAD TO ADVANCING INNOVATION**

# Top 20 Global AI for Drug Discovery Conferences



May 23, 2018  
DoubleTree Suites Boston-Cambridge  
Cambridge, MA



**2<sup>ND</sup> GLOBAL PHARMA R&D  
INFORMATICS & AI CONGRESS**

29-30 OCTOBER 2018 – LONDON, UK



**Artificial Intelligence in Drug Development  
Congress**

27-28 September 2017, London, UK



11-14 September 2018

Congress Center Basel  
Switzerland

Artificial intelligence and blockchain in healthcare



**OXFORD  
GLOBAL**

**2nd Annual Artificial Intelligence in Drug  
Development Congress**

20-21 September 2018, London, UK



11th & 12th July 2018,  
Canary Riverside Plaza Hotel,  
London UK

**AI PHARMA  
INNOVATION  
DRUG DISCOVERY**



**ARTIFICIAL INTELLIGENCE  
TRANSFORMING PHARMA R&D**



**MAX PLANCK ALUMNI ASSOCIATION**

**Artificial Intelligence and Big Data in Pharma**

*Impact on drug development on the role of the industry*

March 21, 2018

Max Planck Institute of Biochemistry, Munich

# Topics Featured at AI for Drug Discovery Conferences

Among the specific topics featured at industry-specific AI in Drug Discovery conferences, those that seem to be emerging as predominant ones being featured to a high degree at several conferences include:

- How BioPharma companies can effectively face the challenge of big data, and the issue of needing to prioritize big data analytics and AI in order to be capable of generating novel insights from the increasing amount of data being generated by the BioPharma industry;
- How AI can expedite the time it takes to go from drug discovery to clinical validation, decreasing the cost of the drug development process;
- How AI can optimize lead generation and predict drug toxicity and adverse effects;
- How AI can be leveraged to create more adaptive, responsive and effective diagnostic and prognostic tools;
- How AI can assist in the development of personalized medicines, targeting drug regimes to the specific omic profiles of select patient demographics;
- How non-AI experts can gain a better understanding of the AI for Drug Discovery process and apply it to their own activities;
- AI and big data analytics as clinical decision support tools;
- Gain a better understanding of the applications and use-cases of AI in Drug Discovery through actionable and practical case studies;
- How advanced AI in Drug Discovery change the regulatory process, and how the regulatory infrastructure of healthcare systems can respond to and be affected by the rise of AI in the BioPharma industry.

# AI for Drug Discovery Becomes a Featured Topic at Top Conferences

Not only are we seeing an increase generally in the number of conferences devoted exclusively to AI in Drug Discovery.

We are also witnessing an increase in the number of presentations, panel discussions and sessions on the topic in the world's leading BioPharma conferences, typically aimed to traditional BioPharma executives.

AI for Drug Discovery panels have appeared such conferences as Financial Times' 2018 Global Pharmaceutical and Biotechnology Conference, at the 2018 Basel Life Sciences Conference, and at the 2018 JP Morgan Healthcare



## Artificial intelligence and blockchain in healthcare

You are here: [basellife.org](#) [BASEL LIFE 2018](#) [BASEL LIFE](#) [Innovation Forums](#)

### Date

Thursday & Friday, 13-14 September 2018

### Chairs

Alex Zhavoronkov (Insilico Medicine, Baltimore, United States)  
Verner De Biasi (GSK, London, Switzerland)

## 36<sup>TH</sup> ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

JANUARY 8, 2018  
SAN FRANCISCO

## FINANCIAL TIMES LIVE

[Home](#) [Coming up](#) [Become a s](#)

3:40pm

### Panel: Envisioning the Future of Diagnostics

Some 70% of medical decisions, it is claimed are driven by diagnostics. As we enter the era of precision medicine, tailored therapeutics and AI, and as ever more rare diseases are investigated, diagnostics will continue to grow and the definition of what constitutes diagnostics will evolve.

# Media Main Trends: Big Pharma On-Boarding AI for Drug Discovery

We are also witnessing an increasing number of articles that discuss the entry of major BioPharma corporations into the AI for Drug Discovery space.

The previous edition of this report notes the big gap between AI for Drug Discovery startups and traditional BioPharma executives, and this updated version attempts to show that that gap has to a large extent now been neutralized, with an increasing number of pharma corporations on-boarding AI for Drug Discovery specialists, assets and projects (see Chapter II).

Writing for Nature News, Nick Fleming reports:

*“An enormous figure looms over scientists searching for new drugs: the estimated US\$2.6-billion price tag of developing a treatment. A lot of that effectively goes down the drain, because it includes money spent on the nine out of ten candidate therapies that fail somewhere between phase I trials and regulatory approval. Few people in the field doubt the need to do things differently. Leading BioPharmaceutical companies believe a solution is at hand. Pfizer is using IBM Watson, a system that uses machine learning, to power its search for immuno-oncology drugs. Sanofi has signed a deal to use UK start-up Exscientia’s artificial-intelligence (AI) platform to hunt for metabolic-disease therapies, and Roche subsidiary Genentech is using an AI system from GNS Healthcare in Cambridge, Massachusetts, to help drive the multinational company’s search for cancer treatments. Most sizeable BioPharma players have similar collaborations or internal programmes. If the proponents of these techniques are right, AI and machine learning will usher in an era of quicker, cheaper and more-effective drug discovery. Some are sceptical, but most experts do expect these tools to become increasingly important. This shift presents both challenges and opportunities for scientists, especially when the techniques are combined with automation (see ‘Here come the robots’). Early-career researchers, in particular, need to get to grips with what AI can do and how best to acquire the skills they need to be employable in the job market of tomorrow.”*

Source: <https://www.nature.com/articles/d41586-018-05267-x>

# Media Main Trends: Big Pharma On-Boarding AI for Drug Discovery

Writing for Pharmaceutical Technology, the organization GlobalData Healthcare writes:

*“More and more, big pharma is partnering with AI-driven companies in hopes of more accurately predicting drug candidates and cutting R&D costs and time, prompting GlobalData to ask—Is AI the future of drug discovery? Pharmaceutical corporation Merck is one such company taking a lead in implementing AI-based solutions in drug discovery. Merck entered the AI space early, in 2012, striking a partnership with Numerate, an AI-based company leveraging algorithms and cloud computing to transform the drug design process. The collaboration was initially developed for Merck to utilize Numerate’s computer-based drug design technology to develop novel small molecule drug leads for an undisclosed cardiovascular disease target. In addition, Merck is working with Atomwise, the creator of AtomNet, which uses deep learning technology for the discovery of novel small molecules. Although the project is confidential, Merck is leveraging Atomwise’s AI-based technology to scan existing medicines that could be redesigned to fight old and upcoming diseases. Merck is just one of many pharmaceutical companies partnering with AI-focused companies to advance drug discovery. Celgene partnered with GNS Healthcare to utilize its Reverse Engineering and Forward Simulation causal machine learning and simulation platform; GSK entered a \$43M drug discovery collaboration with UK-based AI-driven startup Exscientia; Pfizer entered collaboration with IBM Watson for immuno-oncology drug discovery research, and the list goes on.”*

Source: <https://www.pharmaceutical-technology.com/comment/artificial-intelligence-future-drug-discovery/>

# Media Main Trends: AI Can Help Discovery Obscure & Elusive Drug Targets

In addition to the ways in which AI can improve upon the things that pharma companies already do best, we are also seeing an increasing emphasis on the ways in which AI can help pharma companies become more effective at the things they currently struggle with, such as the identification of obscure and elusive drug targets,

Writing for Medium, CoralHealth notes:

*“Virtually all large pharma and academic research institutions are turning towards AI to increase efficiencies and design better drugs against well characterized targets. For example, HER2 is a messenger protein that promotes cell growth and division. HER2 protein is elevated and/or mutated in a quarter of breast cancer patients, with this subtype referred to as HER2-positive or HER2+. The first line treatment for HER2+ breast cancer is a combination of two HER2-targeted antibodies along with docetaxel, a chemotherapeutic agent that is indiscriminately cytotoxic to dividing cells. However, not all HER2-positive patients are receptive to the treatment. AI has identified a candidate experimental pancreatic cancer drug that has the potential to slow or reverse HER2+ breast cancer (Mullin, 2018). In addition, AI is being used to predict druggable interactions and binding sites for RAS, an elusive target which is mutated in a third all cancer patients. RAS proteins are challenging targets due to their interaction with the cellular membrane, involvement in complex signaling pathways and structural flexibility. By using computational approaches, researchers are identifying oncogenic conspirators of RAS, which could be used to guide the development of novel targeted interventions in oncology (Ascr-discovery.science.doe.gov, 2018).”*

Source: <https://www.pharmaceutical-technology.com/comment/artificial-intelligence-future-drug-discovery/>

# Media Main Trends: Largest Barrier Facing AI for Drug Discovery is a Lack of Knowledge & Education Among Pharma Scientists

In a recent Forbes article by Simon Smith, Chief Growth Officer at AI for Drug Discovery startup BenchSci notes that one of the top barriers to AI in Drug Discovery is effective outreach and education within the pharma industry as well as within the broader scientific community.

"We found that 41% of scientists working in drug discovery are unfamiliar with AI. This includes 15% who are very unfamiliar. Pistoia's survey found that 8% know 'next to nothing.' Why aren't more scientists familiar with AI? I have long worked in health tech. So I assumed a conservative culture or concern about data privacy inhibited experimentation. Not so: 18% and 16% of respondents said so, respectively. The top barrier in our survey was "lack of knowledge and expertise about the technology" (62%). Another was "lack of knowledge and expertise about available companies and tools" (42%). Pistoia also found technical expertise the most cited barrier, at 30%. Without deeper knowledge, many scientists will be skeptical."

This is an increasingly voiced concern in the media - the lack of widespread knowledge regarding the impact of AI for Drug Discovery among drug discovery specialists. Furthermore, this insight highlights the important role that drug discovery media and conferences will come to play in the years to come. If it is true that part of BioPharma's previous resistance to AI for Drug Discovery is due to a lack of sufficient understanding, then its increasing visibility in media, in the conference space, and as a featured topic in the biggest traditional BioPharma conferences could serve to enable a greater degree of penetration among the minds of BioPharma executives.

# Media Main Trends: AI Can Help Discovery Obscure & Elusive Drug Targets

In addition to the ways in which AI can improve upon the things that pharma companies already do best, we are also seeing an increasing emphasis on the ways in which AI can help pharma companies become more effective at the things they currently struggle with, such as the identification of obscure and elusive drug targets,

Writing for Medium, CoralHealth notes:

*“Virtually all large pharma and academic research institutions are turning towards AI to increase efficiencies and design better drugs against well characterized targets. For example, HER2 is a messenger protein that promotes cell growth and division. HER2 protein is elevated and/or mutated in a quarter of breast cancer patients, with this subtype referred to as HER2-positive or HER2+. The first line treatment for HER2+ breast cancer is a combination of two HER2-targeted antibodies along with docetaxel, a chemotherapeutic agent that is indiscriminately cytotoxic to dividing cells. However, not all HER2-positive patients are receptive to the treatment. AI has identified a candidate experimental pancreatic cancer drug that has the potential to slow or reverse HER2+ breast cancer (Mullin, 2018). In addition, AI is being used to predict druggable interactions and binding sites for RAS, an elusive target which is mutated in a third all cancer patients. RAS proteins are challenging targets due to their interaction with the cellular membrane, involvement in complex signaling pathways and structural flexibility. By using computational approaches, researchers are identifying oncogenic conspirators of RAS, which could be used to guide the development of novel targeted interventions in oncology (Ascr-discovery.science.doe.gov, 2018).”*

Source: <https://www.pharmaceutical-technology.com/comment/artificial-intelligence-future-drug-discovery/>

## Media Main Trends: AI Can Dramatically Accelerate the Pace of Drug Development

Writing for Inside Big Data, Gunjan Bhardwaj notes: *“Another barrier to the successful development of new treatments is the high attrition rate in the industry. Studies show that only about 9.6% of drugs that start Phase I trials eventually get approved to market. At first glance, this might seem like a good thing. If a drug doesn’t work, or if it is potentially harmful it should never make it to shelves. However, a better way of looking at it is that less of these drugs should make it to trials in the first place. By using the latest big data analytics technologies, pharma companies can better forecast the success of a drug sooner in the development process. This can speed the development of new cures because if unsuccessful drugs are abandoned sooner, there will be more capacity for researching better ones. Healthcare and life sciences companies looking to implement any data solution should do their due diligence in finding qualified partners. Through the use of AI, we can speed the development of new treatments, and democratize access to medical data, making it available to every layer of the healthcare industry.”*

Writing for SingularityHub, Vanessa Bates Ramirez notes: *“To create a new drug, researchers have to test tens of thousands of compounds to determine how they interact. And that’s the easy part; after a substance is found to be effective against a disease, it has to perform well in three different phases of clinical trials and be approved by regulatory bodies. It’s estimated that, on average, one new drug coming to market can take 1,000 people, 12-15 years, and up to \$1.6 billion. There has to be a better way—and now it seems there is. Last week, researchers published a paper detailing an artificial intelligence system made to help discover new drugs, and significantly shorten the amount of time and money it takes to do so. The system is called AtomNet, and it comes from San Francisco-based startup AtomWise. The technology aims to streamline the initial phase of drug discovery, which involves analyzing how different molecules interact with one another—specifically, scientists need to determine which molecules will bind together and how strongly. They use trial and error and process of elimination to analyze tens of thousands of compounds, both natural and synthetic. AtomNet can reportedly screen one million compounds in a day, a volume that would take months via traditional methods.”*

Source: <https://www.pharmaceutical-technology.com/comment/artificial-intelligence-future-drug-discovery/>;  
<https://singularityhub.com/2017/05/07/drug-discovery-ai-can-do-in-a-day-what-currently-takes-months/#sm.0000iwwp9t6mwf2rtqo1fmm5nefj9>

## Main Trends: Large Surge of Industry Activity in 2018

Writing for BioPharmaTrend, Andrii Bavailo notes:

“The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a notable amount of activity over the last several years with a considerable number of initiated research collaborations between AI-driven R&D vendors and top pharmaceutical companies in 2016-2017. A busy beginning of 2018 shows that the area is getting even “hotter” and things start unfolding faster in the emerging “AI for Drug Discovery” space. Judging by the increasing activity in the “AI for Drug Discovery space” over the last two years, it is expected that 2018 will be a year of a more widespread curiosity among BioPharma companies about AI-based technologies and tools. As a consequence, a growing number of new AI-vendors will be pitching in, offering solutions for novel use cases and more flexible collaboration models, and more research initiative will be launched on the side of “big” and “middle” pharma players. It means the market of R&D outsourcing will be growing even faster in 2018, at least in the segment of outsourcing AI, cloud and big data technologies and expertise. On the other hand, AI-vendors will face a more pressing challenge of finding ways to prove their value proposition for the pharmaceutical and biotech partners in more practical and measurable terms -- in order to overcome a growing skepticism fueled by sometimes irresponsibly overhyped claims about “AI revolution” in the mass media.”

Source: <https://singularityhub.com/2017/05/07/drug-discovery-ai-can-do-in-a-day-what-currently-takes-months/#sm.0000iwwp9t6mwf2rtqo1fmm5nefj9>

## Main Trends: BioPharma Will Increasingly Utilize R&D Outsourcing & M&As to Increase their Presence in the AI for Drug Discovery Sphere

Another notable trend noted increasingly often in the media is the comparative disadvantages that pharma corporations have in terms of the internal resources necessary to do AI for Drug Discovery work on-house, and the increasing extent with which BioPharma's role in the AI for Drug Discovery race will take the form of outsourcing to AI and IT corporations, as well as through M&As.

Writing for BioPharmaTrend, Andrii Buvailo notes:

*“With an increasing interest in AI-driven technologies among the leading BioPharmaceutical companies, a strategic focus of pharma and biotech businesses will be further shifting towards R&D outsourcing and M&A activity as means to quickly get access to the required expertise and know-hows. Complex nature of AI-based technologies, a need for costly and sophisticated IT infrastructure, a fast pace of progress in the field, and a relative scarcity of highly skilled data science specialists to support specialized machine learning research -- these are some of the key drivers of the ascending outsourcing trend.”*

Source: <https://www.BioPharmatrend.com/post/34-BioPharmas-hunt-for-artificial-intelligence-who-does-what/>

## Media Main Trends: BioPharma Will Increasing Utilize R&D Outsourcing & M&As to Increase their Presence in the AI for Drug Discovery Sphere

Writing for another article in BioPharmaTrend, Andrii Buvailo adds:

*“An increasing lack of innovation in pharma seems to be among the underlying reasons why drug makers tend to outsource research to academia or CROs. However, it is rare that BioPharmaceutical companies have all the required expertise and infrastructure in-house to fully embrace the new technologies’ potential. Thus, companies more often choose to outsource their research programs to specialized CROs or academic centers focused on a particular area of knowledge and capable of providing a state-of-the-art expertise in certain areas. A vivid example when R&D outsourcing appears to be a smart approach for accessing a novel technology early in the drug discovery process is a collaboration with companies offering artificial intelligence (AI) and machine learning (ML) capabilities for big data analysis, hypothesis probing, accelerating hit exploration activities and identifying hidden dependencies in data patterns. The modern world is characterized by rapidly changing technological paradigms, exponentially growing data, and the increasing role of the interdisciplinary collaboration and expertise. Developing sophisticated in-house infrastructure and substantially expanding the count of staff with specific expertise in advanced areas of research is not only costly but also risky for a pharmaceutical company. Especially it is true at the earliest stages of drug discovery process when the uncertainty is the highest. Maintaining only the most important core functions and competencies, while outsourcing research-intensive programs with yet uncertain results to specialized CROs or academic labs, seems to be a reasonable strategy.”*

Source: <https://www.BioPharmatrend.com/post/30-pharma-rd-outsourcing-is-on-the-rise/>

# Profile Section

# Top-20 Conferences on AI for R&D and Drug Discovery 2018-2019

Name	Date	Location	Website
2nd Annual Artificial Intelligence in Drug Development Congress	20 - 21 September 2018	UK	<a href="https://www.oxfordglobal.co.uk/artificialintelligence-congress/">https://www.oxfordglobal.co.uk/artificialintelligence-congress/</a>
2nd Global Pharma R&D Informatics and AI Congress	29 - 30 October 2018	UK	<a href="http://www.global-engage.com/event/pharma-informatics-congress/">http://www.global-engage.com/event/pharma-informatics-congress/</a>
Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development	19 - 20 June 2018	EU	<a href="https://www.bisgrp.com/portfolio/conferences/pharmaceutical/advanced-machine-learning-and-artificial-intelligence-for-drug-discovery-development">https://www.bisgrp.com/portfolio/conferences/pharmaceutical/advanced-machine-learning-and-artificial-intelligence-for-drug-discovery-development</a>
AI Health & Pharma Summit	14 June 2018	UK	<a href="https://theaisummit.com/health/">https://theaisummit.com/health/</a>
AI in Pharma Summit 2018	9 October 2018	US	<a href="https://www.aiinpharma.com/">https://www.aiinpharma.com/</a>
AI in Pharma: Opportunities & Challenges	12 June 2018	UK	<a href="https://telecomstechacademy.knect365.com/ai-in-pharma-opportunities-challenges/">https://telecomstechacademy.knect365.com/ai-in-pharma-opportunities-challenges/</a>
BioTech Pharma Summit: AI Pharma 2018	10 - 11 September 2018	Japan	<a href="https://10times.com/ai-pharma-japan">https://10times.com/ai-pharma-japan</a>
AI Pharma Innovation: Drug Discovery Summit	26 - 28 February 2018	US	<a href="http://ai-drugdiscovery.com/">http://ai-drugdiscovery.com/</a>
Artificial Intelligence and Big Data in Pharma	21 March 2018	EU	<a href="http://www.mpg-alumni.de/conferences/aiworkshop/">http://www.mpg-alumni.de/conferences/aiworkshop/</a>
Artificial Intelligence and Machine Learning for Drug Discovery	27 November 2018	EU	<a href="http://www.worldpreclinicaeurope.com/AI-ML-Drug-Discovery">http://www.worldpreclinicaeurope.com/AI-ML-Drug-Discovery</a>

# Top-20 Conferences on AI for R&D and Drug Discovery 2018-2019

Name	Date	Location	Website
Artificial Intelligence for Drug Discovery	23 May 2018	US	<a href="https://www.BioPharmatrend.com/post/57-artificial-intelligence-for-drug-discovery-may-23-2018-cambridge-ma-usa/">https://www.BioPharmatrend.com/post/57-artificial-intelligence-for-drug-discovery-may-23-2018-cambridge-ma-usa/</a>
BioData World	28 - 29 November 2018	Switzerland	<a href="https://www.terrapinn.com/conference/biodata/index.stm">https://www.terrapinn.com/conference/biodata/index.stm</a>
Artificial Intelligence in Pharma Industry Summit	19- 20 February 2018	EU	<a href="https://www.asdevents.com/event.asp?id=17278">https://www.asdevents.com/event.asp?id=17278</a>
Artificial intelligence to speed up drug discovery: the revolutionary road to advancing innovation	4 December 2018	EU	<a href="https://www.biofit-event.com/conference/artificial-intelligence-speed-drug-discovery-revolutionary-road-advance-innovation/">https://www.biofit-event.com/conference/artificial-intelligence-speed-drug-discovery-revolutionary-road-advance-innovation/</a>
Artificial Intelligence Transforming Pharma R&D	21 February 2018	US	<a href="https://benevolent.ai/events/previous/artificial-intelligence-transforming-pharma-r-d/">https://benevolent.ai/events/previous/artificial-intelligence-transforming-pharma-r-d/</a>
BASEL LIFE: Showcasing Europe's Excellence in Life Sciences	11 - 14 September 2018	Switzerland	<a href="https://www.basellife.org/basel-life-2018/basel-life/innovation-forums/scientific-programme/artificial-intelligence-and-blockchain-in-healthcare.html">https://www.basellife.org/basel-life-2018/basel-life/innovation-forums/scientific-programme/artificial-intelligence-and-blockchain-in-healthcare.html</a>
AI Driven Healthcare Conference Track. GTC 2019	18 - 22 March 2019	US	<a href="https://www.nvidia.com/en-us/gtc/topics/healthcare-and-life-sciences/">https://www.nvidia.com/en-us/gtc/topics/healthcare-and-life-sciences/</a>
Pharma AI & IoT 2018	11 - 12 July 2018	UK	<a href="http://www.virtueinsight.com/pharma/Pharma-AI-IoT-2018/">http://www.virtueinsight.com/pharma/Pharma-AI-IoT-2018/</a>
SMI's 2nd annual Drug Discovery conference	21 - 22 March 2018	UK	<a href="https://www.drugtargetreview.com/news/29432/new-2018-role-artificial-intelligence-drug-discovery/">https://www.drugtargetreview.com/news/29432/new-2018-role-artificial-intelligence-drug-discovery/</a>
AI Applications Summit	25 - 26 October 2018	US	<a href="https://pharmaphorum.com/events/ai-applications-summit-BioPharma/">https://pharmaphorum.com/events/ai-applications-summit-BioPharma/</a>

# 2nd Annual Artificial Intelligence in Drug Development Congress

**Date:** 20 - 21 September 2018

**Location:** London, UK

**Website:** <https://www.oxfordglobal.co.uk/artificialintelligence-congress/>



2nd Annual  
Artificial Intelligence in Drug  
Development Congress

300+ delegates  
30+ presentations  
3 Interactive Streams  
2 Free Live Webinars

 @Conf\_AI  
PharmatecSeries18

20-21 September 2018, London, UK

The banner features a dark blue background with white text. On the right side, there is a graphic of a glowing blue molecular structure or network. The text is arranged in a clear, hierarchical manner, providing key details about the event.

2nd Annual Artificial Intelligence in Drug Development Congress is organized by Oxford Global Marketing Ltd. At the conference will be present over 300 artificial intelligence and pharmaceutical IT attendees representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions, as well over 30 presentations, case studies and panel discussions focussed on the innovative application of artificial intelligence in drug discovery and cheminformatics, alongside machine learning in clinical trials and big data.

Across the two days, the congress will bring together over 150 senior level attendees from major pharma companies, emerging biotechs and clinical research institutions. Reflecting the popularity of the inaugural event, the agenda has been extended for 2018 to showcase the range of innovative research being done in this field. This event is part of the flagship PharmaTec Series: the co-located events enable greater discussion on the key topics in pharmaceutical and digital technologies, from Real World Evidence to wearables.

# 2nd Global Pharma R&D Informatics and AI Congress

**Date:** 29 - 30 October 2018

**Location:** London, UK

**Website:**

<http://www.global-engage.com/event/pharma-informatics-congress/>



Global Engage is pleased to announce the 2nd Global Pharma R&D Informatics and AI Congress: Europe which is co-located with the 2nd Medicinal Chemistry Summit: Europe and will be held in London on 29-30 October, 2018. Last year these conferences attracted over 250 industry and academic leaders, and Global Engage is looking forward to developing upon the great feedback it received from the participants.

The development of drugs is both a timely and expensive process, but with advancements in AI, data analysis and system integration, the industry is accelerating its capacity to create more targeted and effective treatments. This conference is responding to the computational transformation within the pharmaceutical industry, bringing together experts working in all areas of pharmaceutical R&D IT and discovery informatics across more than 7 hours of networking time.

# Advanced Machine Learning and Artificial Intelligence for Drug Discovery & Development

**Date:** 19 - 20 June 2018

**Location:** Berlin, Germany

**Website:**

<https://www.bisgrp.com/portfolio/conferences/pharmaceutical/advanced-machine-learning-and-artificial-intelligence-for-drug-discovery-development>



The conference will be attended by presidents, vice presidents, directors, heads/managers of: Bioinformatics, Analytics, Clinical Development, Data Scientists, Artificial Intelligence Scientists, Machine learning Scientists, Health Innovation, Drug Discovery, Scientific, IoT, Genomics, Diagnostics, IT, Computer Science, Clinical, Drug Development.

The conference is organized by BIS Group, an exclusive platform supporting innovative and forward thinking companies in Oil & Gas, Energy, Construction, Telecommunications, Pharmaceutical, Management and Financial Services and empowering them with cutting-edge information and the best practices for today's fast changing markets. BIS Group's business forums are exclusive and for global business leaders and experts only. They carefully pick high caliber speakers to ensure the best possible panel with the most diverse range of expertise.

# AI Health & Pharma Summit

**Date:** 14 June, 2018

**Location:** London, UK

**Website:** <https://theaisummit.com/health/>



The inaugural AI Health & Pharma Summit brought together the key stakeholders in pharma and healthcare to transform and enhance scientific research based on better decision-making, optimized innovation, improved efficiency of clinical trials, and new tool creation for physicians, consumers, insurers, and regulators.

As part of the world's largest AI event, The AI Summit London gathers 10,000 Expo visitors, 3,000 conference delegates, 300 speakers across 7 theatres (including dedicated technical streams for developers and engineers); it is now the flagship AI show of London Tech Week, supported by The Mayor of London and the UK Government.

# AI in Pharma Summit 2018

**Date:** 9 October 2018

**Location:** Boston, MA, USA

**Website:** <https://www.aiinpharma.com/>



The AI in Pharma Summit aims to: develop and define how AI and machine learning will transform drug discovery and development. Understand and overcome scientific and commercial challenges through case studies, workshops and discussions. Advance collaboration and partnerships among senior executives.

Jaquie Finn, Head of Digital Health, will be speaking at the summit. Jaquie provides strategic guidance and practical support for clients transitioning their business model to include a digital element. This includes device connectivity, data science, launch strategies, behavioural science and digital service design.

Further details, including stand number, to follow in due course.

# AI in Pharma: Opportunities & Challenges

**Date:** 12 June 2018

**Location:** London, UK

**Website:**

<https://telecomstechacademy.knect365.com/ai-in-pharma-opportunities-challenges/>



The directors and senior leaders in Pharma, Biopharma, and Biotech, who are tasked with creating business strategy and implementing new technology should attend. These include: Chief Information Officers, Chief Scientists, Chief Digital, Information Officers, Chief Clinical Officers, Clinical Directors of Innovation, Directors of Bioinformatics, Heads of Artificial Intelligence, Chief Technology Officers, Senior VP and Chief Analytics Officers, Chief Operating Officers, Development and Trial.

This exclusive one-day think-tank gave the practical knowledge and tools to steer your organisation towards an AI-first future and network with executives in this exclusive setting. Led by two experts in the field of Data Science, this C-level session delved into the latest ML use cases, showing attendees the current and likely future applications of AI in Pharma.

# BioTech Pharma Summit: AI Pharma 2018

**Date:** 10-11 September 2018

**Location:** Tokyo, Japan

**Website:** <https://10times.com/ai-pharma-japan>



On 10 & 11 September 2018, Tokyo (Japan) will host the BioTech Pharma Summit: AI Pharma 2018 conference. This year's event will bring together some of the most prominent thought leaders in artificial intelligence for the pharmaceutical industry, pharmaceutical industry executives, regulators and academics and it's committed to help large pharma, biotech, leading research institutes and technology pioneers overcome key challenges in the adoption and application of AI along the R&D pipeline to optimize the discovery and development of novel therapies with better outcomes, faster and more cost effectively.

# AI Pharma Innovation: Drug Discovery Summit

**Date:** 26 - 28 February 2018

**Location:** San Francisco, CA, USA

**Website:** <http://ai-drugdiscovery.com/>



The AI Pharma Innovation: Drug Discovery Summit is a solution led event solely focused on harnessing the power of AI & machine learning to enhance and accelerate drug discovery productivity towards the development of safe, effective and value-based drugs.

This event brings together the leading scientists, technology developers, and key decision makers in the pharmaceutical and biotechnology industries to assess and address key challenges standing in the way of the adoption and practical application of AI and machine learning technologies across the early phases of drug discovery value chain in order to increase levels of pharmaceutical innovation and maximize drug discovery assets.

# Artificial Intelligence and Big Data in Pharma

**Date:** 21 March 2018

**Location:** Munich, Germany

**Website:** <http://www.mpg-alumni.de/conferences/aiworkshop/>



New technologies, such as Big data and Artificial Intelligence (AI), are progressively changing the process of drug and clinical development. Currently these new technologies are being adopted by big pharma players, such as Novartis. Smaller biotech companies can also benefit from applying Big data and AI to their process of drug and clinical development.


This workshop aimed to provide an overview about Big data and AI to non-experts of this field working in biotech. Selected topics include AI in personalized medicine, drug discovery, pre-clinical and clinical development. Besides presentations on these topics, there was a panel discussion in which invited experts shared their views on the advantages and challenges of implementing Big data and AI on biotech companies working in drug development.

# Artificial Intelligence and Machine Learning for Drug Discovery

**Date:** 27 November 2018

**Location:** Lisbon, Portugal

**Website:** <http://www.worldpreclinicaeurope.com/AI-ML-Drug-Discovery>



Artificial Intelligence (AI) and Machine Learning (ML) are more than just buzz words being used in the pharmaceutical and biotechnology industry. There is now a steady stream of publications and evidence outlining what these terms really mean, how they can be applied in a drug discovery and development setting, and how much value they add in terms of saving time, effort and costs.

Cambridge Healthtech Institute's Inaugural AI & Machine Learning for Drug Discovery symposium will bring together computational and bioinformatics experts along with discovery scientists to discuss how some of these technologies and platforms are being used and how well they are living up to their promise. It will include a diverse set of talks that will highlight how AI and ML can be used for target identification, drug design and optimization, predicting drug toxicity and adverse events. This unique one-day symposium will help attendees meet and interact with experts and peers from around the world to share ideas and gain some understanding about the opportunities and limitations in using these emerging informatics tools and platforms.

# Artificial Intelligence for Drug Discovery

**Date:** 23 May 2018

**Location:** Cambridge, MA, USA

**Website:**

<https://www.biopharmatrend.com/post/57-artificial-intelligence-for-drug-discovery-may-23-2018-cambridge-ma-usa/>



Industry experts and colleagues at the Artificial Intelligence for Drug Discovery conference on May 23 in Cambridge, MA discussed the modernization of the drug production process through these disruptive innovations and identified how to extract maximum value from and leverage the massive amounts of data that is continuously being generated.

This event is the ideal platform for senior leadership and academia alike to explore critical advancements, exchange solutions, and collaborate with prominent industry thought leaders. The AI for Drug Discovery Summit covered topics such as social adoption, data partnerships, enterprise adoption, data integrity, validation, computing principles, novel applications, partnerships and more.

# BioData World Congress 2018



**Date:** 28 - 29 November 2018

**Location:** Basel, Switzerland

**Website:** <https://www.terrapinn.com/conference/biodata/index.stm>

BioData World Congress 2018 is Europe's flagship event for decision makers and thought leaders working in omics, diagnostics and R&D from across Europe and beyond. This year's event will be bigger than ever with 450+ senior decision makers in attendance.

BioData World Congress 2018 will bring together key stakeholders from across the life science and technology industry to discuss and debate how to come together to improve efficiencies within bio IT and biodata to the benefit of patients worldwide.

# Artificial Intelligence in Pharma Industry Summit

**Date:** 19- 20 February 2018

**Location:** Berlin, Germany

**Website:** <https://www.asdevents.com/event.asp?id=17278>



This premier B2B event brought together experts from all levels of the value chain to ensure maximum knowledge transfer and professional exchange; elaborate on the best practices within the companion industry. Attendees could hear and learn about their experiences on latest trends on companion development, to network and enjoy excellent mix of case studies, interactive panel discussions, speed networking and workshops.

# Artificial intelligence to speed up drug discovery: the revolutionary road to advancing innovation

**Date:** 4 December 2018

**Location:** France

**Website:** <https://www.biofit-event.com/conference/artificial-intelligence-speed-drug-discovery-revolutionary-road-advance-innovation/>



Companies are now using machine learning in highly specific ways to streamline and improve many day-to-day biomedical research tasks. The use of AI has shifted from generalist tasks to purpose-built tools with numerous applications to speed up drug discovery at all the different research stages.

The panel will address some of the uses of AI, ultimately potentially cutting R&D costs by aggregating and synthesising information, repurposing existing drugs, generating and validating novel drug candidates, designing drugs and preclinical experiments, etc.

# Artificial Intelligence Transforming Pharma R&D

**Date:** 21 Feb 2018

**Location:** Boston, MA, USA

**Website:**

<https://benevolent.ai/events/previous/artificial-intelligence-transforming-pharma-r-d/>



In 2016, total expenditure on prescription drugs in the US was estimated at \$450 billion. During this year, almost half of the US population took at least one prescription medicine every month. Yet despite the heavy need, successfully bringing a new therapeutic to market can take up to 12 years and log up almost \$1 billion in research and development costs.

It is essential that Artificial Intelligence Transforming Pharma R&D finds ways to streamline this process, removing inefficiencies and unnecessary costs, while bringing efficacious prescription drugs to the population as soon as possible. Artificial Intelligence Transforming Pharma R&D believes that Artificial Intelligence offers the best solutions to solve these issues.

# BASEL LIFE: Showcasing Europe's Excellence in Life Sciences

**Date:** 11–14 September 2018

**Location:** Switzerland

**Website:**

<https://www.baselife.org/basel-life-2018/basel-life/innovation-forums/scientific-programme/artificial-intelligence-and-blockchain-in-healthcare.html>



The recent advances in deep learning techniques revolutionized the Artificial Intelligence (AI) and facilitated its application in the pharmaceutical industry. Alongside AI, Blockchain technology is also rapidly gaining popularity in the biopharmaceutical sector. These two technologies are remarkably converging with each other and enabling new, previously unthinkable applications in healthcare.

BASEL LIFE is Europe's leading congress in the Life Sciences, showcasing cutting-edge science and technology. It brings together preeminent researchers in the field, and offers talented young scientists the possibility to present themselves. Basel is the heart of Europe's Life Sciences landscape.

# AI Driven Healthcare Conference Track. GTC 2019

**Date:** 18 - 22 March 2019

**Location:** San Jose, CA, USA

**Website:**

<https://www.nvidia.com/en-us/gtc/topics/healthcare-and-life-sciences/>



Silicon Valley

NVIDIA's GPU Technology Conference (GTC) is the premier AI and deep learning event, providing you with training, insights, and direct access to experts from NVIDIA and other leading organizations.

Physicians, scientists, and researchers come together for impactful sessions on the future of AI across healthcare, pharmaceutical, and biomedical research at GTC. Explore how industry thought leaders use GPU-driven deep learning solutions to unlock the potential of evidence-based precision medicine, targeted therapeutics, and population healthcare strategies. These include everything from big 'omics and medical imaging to drug discovery and development.

# Pharma AI & IoT 2018

**Date:** 11-12 July 2018

**Location:** London, UK

**Website:** <http://www.virtueinsight.com/pharma/Pharma-AI--IoT-2018/>



Pharma AI & IoT 2018 will provide insight into the current state of play in the EU & US and stimulate debate, in a multi-stakeholder setting, on the vital role of technology impact in the sustainability of pharma and healthcare systems.

Beyond a comprehensive outlook of key European market access policies, the speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding latest technologies that are being analysed towards the pharma and healthcare. This event will provide an important platform for stakeholders to discuss and share best practices in furthering technology development in pharma and healthcare.

# SMI's 2nd annual Drug Discovery conference

**Date:** 21-22 March 2018

**Location:** London, UK

**Website:**

<https://www.drugtargetreview.com/news/29432/new-2018-role-artificial-intelligence-drug-discovery/>



SMI's 2nd annual Drug Discovery conference discussed the role of artificial intelligence (AI) in the Drug Discovery process. Leading experts from ETH Zurich, Exscientia, BenvolentAI and Astrazeneca spoke on this subject. These highly acclaimed professionals were discussing Artificially Intelligent Drug Design, Transforming Small Molecule Drug Discovery Using Artificial Intelligence, Disrupting Drug Discovery with AI and Machine Learning for Smarter Drug Discovery.

The event also covered an array of topics which included Advancements in Small Molecule Therapeutics, Discovering New Experimental Technologies and Exploring Alternate Approaches & Modalities.

# AI Applications Summit

**Date:** 25 - 26 October 2018

**Location:** Boston, MA, USA


**Website:**

<https://pharmaphorum.com/events/ai-applications-summit-biopharma/>



The AI Applications in Biopharma Summit 2018 is the only event to convene key strategic biopharma stakeholders and data driven disruptors to discuss their experiences, obstacles, opportunities for partnerships, and strategies to implement AI technologies in the research and drug development process.

The AI Applications Summit provides the opportunity to discuss the practical steps for implementing these technologies to achieve the greatest impact and ROI. The event will enable industry leaders to find partners to help keep the AI in Biopharma movement growing and moving forward.



DEEP  
KNOWLEDGE  
ANALYTICS



### Deep Knowledge Analytics (DKA) Disclaimer

The information and opinions in this report were prepared by Deep Knowledge Analytics. The information herein is believed by DKA to be reliable but DKA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DKA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of DKA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DKA and are subject to change without notice. DKA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.